Skip to main
IMTX

Immatics NV (IMTX) Stock Forecast & Price Target

Immatics NV (IMTX) Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 80%
Buy 20%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Immatics NV demonstrates a strong fundamental outlook driven by its extensive patent protection for innovative T-cell redirecting immunotherapies, which solidifies its competitive advantage in the oncology sector. The company has shown promising clinical trial results, particularly in cutaneous melanoma and ovarian cancer, with an upgraded launch probability translating to a significant €711.3 million global risk-adjusted sales forecast by 2035. Furthermore, Immatics's compelling clinical data, including a 50% overall response rate and a median progression-free survival that exceeds competitive benchmarks, further strengthens its position in the market.

Bears say

Immatics NV faces significant financial uncertainties due to various risks, including research and development challenges, regulatory hurdles, and the potential emergence of competitors, which may hinder expected product sales. The company is also exposed to potential delays in achieving clinical trial endpoints, which could impede its path to profitability and adversely affect its financial projections. Furthermore, Immatics may need to pursue additional capital through equity financing, raising concerns over share dilution for existing shareholders and negatively impacting the overall financial outlook.

Immatics NV (IMTX) has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 80% of analysts recommend a Strong Buy, 20% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Immatics NV and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Immatics NV (IMTX) Forecast

Analysts have given Immatics NV (IMTX) a Strong Buy based on their latest research and market trends.

According to 5 analysts, Immatics NV (IMTX) has a Strong Buy consensus rating as of Mar 21, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $19, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $19, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Immatics NV (IMTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.